King of Prussia, PA, June 29, 2018 --(PR.com
)-- Devon MD is pleased to announce that they have entered into a strategic agreement with Wound Management Technologies that makes them their authorized distributor for HemaQuell Hemostat in China, South Korea, India, Thailand, Singapore, Malaysia and Australia. This partnership focuses on expanding Devon MD’s product offering to customers overseas by entering the company into the acute surgical market.
"We are extremely excited to enter into this distribution agreement of HemaQuell Hemostat which expands our product line of medical devices to include biomaterials as well,” said Dr. John A. Bennett, CEO Devon MD. “HemaQuell Hemostat is an innovative solution that will integrate into our sales and growth strategy in foreign healthcare markets.”
HemaQuell Hemostat is a new kind of water-soluble bone hemostat that controls bleeding from bone surfaces on application. It is delivered in a unique applicator that allows surgeons to directly apply the product on bleeding bone surfaces. It is used in a wide variety of surgical cases including orthopedic, cranial, cardiothoracic, spinal, and podiatric procedures.
“HemaQuell Hemostat will stop bleeding as soon as it is applied to cut or damaged bone surfaces and is completely resorbed in 2 -7 days," noted Robert Mart, Vice-President of WNDM Medical. “Studies have shown that it does not delay bone fusion or healing."
About Devon MD
Devon MD, a US division of Devon Medical Products (Jiangsu) LTD, manufactures portable DVT prevention devices, NPWT devices and lymphedema devices. Pioneers in preventive DVT care for post-surgery patients, travelers, high-risk pregnancy patients and general patients at risk to DVT. The foundation of Devon MD was built off of a long-standing business specializing in the medical and healthcare space, the Devon International Group. For more information please visit devonmd.com
About WNDM Medical Inc.
With its No. 1 goal of improving patient outcomes, WNDM Medical Inc. develops, markets and distributes biotechnology products to physicians, hospitals, and clinics. It has a strong history of developing long-term strategic partnerships with a focus on products that fuse nature and science with medicine. Its primary products are in the $11 billion U.S. consumable medical device market and the $1.5 billion biomaterials market. WNDM Medical sells and distributes CellerateRX®/CRXα® Surgical Activated Collagen® Adjuvant and HemaQuell® Resorbable Bone Hemostat. For more information, visit WNDM.com.